2nd Quarter - Report

EXPRESS SCRIPTS, INC. for EXPRESS SCRIPTS, INC.

Firm
Client
Income
—
Expenses
$815,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Taxation/Internal Revenue Code TAX

Implementation of tax provisions of the ACA and tax reform policies.

LobbyistCovered position, as disclosed
CHRISTOPHER DAVIS —
JONAH C HOUTS —
EMILY A KATZ —
GARY J KLINE —
SERGIO SANTIVIAGO —

Contacted: Federal Trade Commission (FTC); Internal Revenue Service (IRS); Medicare Payment Advisory Commission (MedPAC); Office of Personnel Management (OPM); Congressional Budget Office (CBO); Health & Human Services, Dept of (HHS); Executive Office of the President (EOP); White House Office; Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Government Accountability Office (GAO); Labor, Dept of (DOL); Health Resources & Services Administration (HRSA); Centers For Medicare and Medicaid Services (CMS); SENATE

Defense DEF

Pharmacy issues related to the annual defense authorization and implementation of the 2018 NDAA.

LobbyistCovered position, as disclosed
CHRISTOPHER DAVIS —
MICHAEL DONNELLY —
JONAH C HOUTS —
EMILY A KATZ —
GARY J KLINE —
LISA CHRISTINE LE GETTE —
SERGIO SANTIVIAGO —

Contacted: HOUSE OF REPRESENTATIVES; Internal Revenue Service (IRS); Health Resources & Services Administration (HRSA); Federal Trade Commission (FTC); Health & Human Services, Dept of (HHS); Government Accountability Office (GAO); Congressional Budget Office (CBO); Food & Drug Administration (FDA); Office of Personnel Management (OPM); SENATE; Labor, Dept of (DOL); White House Office; Medicare Payment Advisory Commission (MedPAC); Centers For Medicare and Medicaid Services (CMS); Executive Office of the President (EOP)

Health Issues HCR

Regulatory policies related to the health reform law, including drug benefits and disclosure. Implementation of HITECH. Prescription drug affordability issues, including biosimilars. Reforms to Medicaid and Exchange markets.

LobbyistCovered position, as disclosed
CHRISTOPHER DAVIS —
JONAH C HOUTS —
EMILY A KATZ —
GARY J KLINE —
SERGIO SANTIVIAGO —

Contacted: Health Resources & Services Administration (HRSA); Internal Revenue Service (IRS); Government Accountability Office (GAO); SENATE; Congressional Budget Office (CBO); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Office of Personnel Management (OPM); Executive Office of the President (EOP); White House Office; Health & Human Services, Dept of (HHS); Labor, Dept of (DOL); Federal Trade Commission (FTC); Medicare Payment Advisory Commission (MedPAC)

Medicare/Medicaid MMM

Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Researching and responding the Administration's America's Patients First drug pricing blueprint. Medicare Part B reforms. S. 637; HR 1920; HR 1939. Medical utilization management and Medicare Advantage program policy and operations; S. 2553 and S 2554 - Prohibition on pharmacy "gag clauses."

LobbyistCovered position, as disclosed
CHRISTOPHER DAVIS —
JONAH C HOUTS —
EMILY A KATZ —
GARY J KLINE —
LISA CHRISTINE LE GETTE —
SERGIO SANTIVIAGO —

Contacted: Labor, Dept of (DOL); Internal Revenue Service (IRS); Health Resources & Services Administration (HRSA); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); White House Office; Executive Office of the President (EOP); Federal Trade Commission (FTC); Medicare Payment Advisory Commission (MedPAC); Office of Personnel Management (OPM); Health & Human Services, Dept of (HHS); SENATE; Congressional Budget Office (CBO); Centers For Medicare and Medicaid Services (CMS); Government Accountability Office (GAO)

Bills named: S. 2553 (115th), H.R. 1939 (115th), S. 637 (115th), H.R. 1920 (115th)

Pharmacy PHA

Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025; S. 2553 and S. 2554.

LobbyistCovered position, as disclosed
CHRISTOPHER DAVIS —
JONAH C HOUTS —
EMILY A KATZ —
GARY J KLINE —
LISA CHRISTINE LE GETTE —
SERGIO SANTIVIAGO —

Contacted: Medicare Payment Advisory Commission (MedPAC); Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); White House Office; Congressional Budget Office (CBO); Federal Trade Commission (FTC); Food & Drug Administration (FDA); Labor, Dept of (DOL); Health Resources & Services Administration (HRSA); Internal Revenue Service (IRS); HOUSE OF REPRESENTATIVES; Office of Personnel Management (OPM); Executive Office of the President (EOP); SENATE; Government Accountability Office (GAO)

Bills named: S. 788 (115th), S. 2554 (115th), S. 2553 (115th), H.R. 1854 (115th), H.R. 2025 (115th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.